Amphastar Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Amphastar Pharmaceuticals, Inc. on June 9, 2016. The report details the results of the Company's Annual Meeting of Stockholders held on the same date at its principal executive offices in Rancho Cucamonga, California.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
No material changes to financial operations or business strategy are reported in this filing. The document serves to disclose the outcome of stockholder votes regarding board composition and auditor appointment.
Outlook, Risks, and Unusual Items
The filing contains no management commentary on future guidance, risks, contingencies, or unusual items. The primary content is the tabulation of votes for director elections and the ratification of the independent auditor.
Key Facts for Investors
- Director Elections: All three Class III director nominees (Jack Yongfeng Zhang, Richard Prins, and Stephen B. Shohet) were duly elected to serve until the 2019 annual meeting.
- Voting Results: Significant broker non-votes (8,947,664 shares) were recorded for the director elections, while the "For" votes exceeded 24 million shares for each nominee.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016.
- Auditor Vote Breakdown: The ratification received 34,922,754 "For" votes, 289,123 "Against" votes, and 201,856 abstentions.